Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the ...

UT Health San Antonio Multispecialty and Research Hospital is the first hospital in Texas to approve a non-narcotic ...

Xifyrm is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics.

Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the debut of a powerful new ...

UT Health San Antonio Multispecialty and Research Hospital says it’s the first in Texas to add a new non-opioid medication to ...

Innocan has initiated regulatory submissions in support of advancing LPT-CBD into human clinical trials. This progress marks ...

US FDA approves Azurity Pharma’s Xifyrm for management of moderate-to-severe pain in adults: Woburn, Massachusetts Thursday, June 12, 2025, 12:00 Hrs [IST] Azurity Pharmaceutica ...

Delivered as a once-daily 30 mg/mL IV bolus injection over 15 seconds, Xifyrm can be used alone or alongside non-NSAID ...

Researchers at Seoul National University Hospital applied 'Enhanced Recovery After Surgery (ERAS)' to gastric cancer surgery ...

Positive effects of ART26.12 were observed in a surgical rat model of osteoarthritis, in which either single or repeated oral doses of Artelo’s FABP5 inbitor increased the ability of rats to bear ...